Skip to content

Balance Performance and Corticomotor Inhibition in PD

Relationship Between Balance Performance and Corticomotor Inhibition in Individuals With Parkinsons' Disease

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05066659
Enrollment
50
Registered
2021-10-04
Start date
2021-10-08
Completion date
2022-09-08
Last updated
2021-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

Parkinson's disease; Transcranial magnetic stimulation; Motor cortex; Corticomotor inhibition; Balance performance

Brief summary

Postural instability is one of the motor features of Parkinson's disease (PD). Most patients will develop balance dysfunction, and they may get worse with disease progression. According to previous studies, people with PD had abnormal changes in corticomotor excitability, especially disinhibition in the primary motor cortex (M1). Some evidence had shown that the cortical function in the M1 is crucial for the pathophysiology of the underlying motor symptoms in PD. Furthermore, neurostimulation over the M1 could modulate the corticomotor excitability in individuals with PD, and then improve their motor and also balance performance. However, whether the impaired corticomotor inhibition relates to balance dysfunction in people with PD is still unknown. In this study, the purpose is to investigate the possible relationship between corticomotor inhibition and balance performance in individuals with PD. However, the postural position during TMS measurement may affect the corticomotor excitability. To further establish the above-mentioned relationship, the secondary purpose is to explore and confirm whether the postural position will influence the correlation.

Interventions

None listed

Sponsors

National Yang Ming Chiao Tung University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* the Hoehn and Yahr stage between 1 and 3 * age 40 to 80 years * a stable treatment of anti-PD medications

Exclusion criteria

* any contraindications of TMS * any injury histories or disorders affecting balance * any neurosurgery experience * neurologic conditions other than PD * the Mini-mental State Examination (MMSE) score \< 24

Design outcomes

Primary

MeasureTime frameDescription
Intracortical inhibition20 minutesShort-interval intracortical inhibition assessed by transcranial magnetic stimulation
Corticospinal inhibition20 minutesCortical silent period assessed by transcranial magnetic stimulation
Static balance3 minutesSharpened Romberg test
Dynamic balance5 minutesFunctional reach test
Functional balance15 minutesMini-Balance Evaluation Systems Test

Countries

Taiwan

Contacts

Primary ContactYea-Ru Yang, PhD
yryang@nycu.edu.tw886228267279

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026